J Korean Diabetes.  2023 Sep;24(3):120-126. 10.4093/jkd.2023.24.3.120.

2023 Clinical Practice Guidelines for Diabetes

• Moon MK

• KMID: 2546628
• DOI: http://doi.org/10.4093/jkd.2023.24.3.120

Abstract

The Committee on Clinical Practice Guidelines of the Korean Diabetes Association updated the previous clinical practice guidelines for Korean adults with diabetes and prediabetes and published the eighth edition in May 2023. We performed a comprehensive systematic review of recent clinical trials and evidence suitable for the Korean population that could be applicable to real-world practice. These guidelines were developed to enable all healthcare providers including physicians, diabetes experts, and certified diabetes educators nationwide to best care for individuals with diabetes in a clinical practice setting. The recommendations for screening, medical nutrition therapy, pharmacologic therapy for adults with type 2 diabetes, and obesity, hypertension, and lipid management were revised and updated. The use of real-time continuous glucose monitoring (CGM) devices was recommended for adults with type 1 diabetes and adults with type 2 diabetes treated with multiple insulin injections, and additional CGM metrics were added to the blood glucose control target.

Keyword

Diabetes mellitus, type 2; Diabetic nephropathies; Drug therapy; Practice guideline

Figure

• 

  Fig. 1. Treatment algorithm in patients with diabetic kidney disease. Adapted from the article of Choi et al. (Diabetes Metab J 2023;47:575-94) [8] under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license.

Reference

1.Bae JH., Han KD., Ko SH., Yang YS., Choi JH., Choi KM, et al. Diabetes fact sheet in Korea 2021. Diabetes Metab J. 2022. 46:417–26.

2.Yang YS., Han BD., Han K., Jung JH., Son JW; Taskforce Team of the Obesity Fact Sheet of the Korean Society for the Study of Obesity. Obesity fact sheet in Korea, 2021: trends in obesity prevalence and obesity-related comor-bidity incidence stratified by age from 2009 to 2019. J Obes Metab Syndr. 2022. 31:169–77.

3.Ha KH., Lee KA., Han KD., Moon MK., Kim DJ. Diabetes screening in South Korea: a new estimate of the number needed to screen to detect diabetes. Korean J Intern Med. 2023. 38:93–100.

4.Lee KA., Kim DJ., Han K., Chon S., Moon MK; Committee of Clinical Practice Guideline of Korean Diabetes Association. Screening for prediabetes and diabetes in Korean nonpregnant adults: a position statement of the Korean Diabetes Association, 2022. Diabetes Metab J. 2022. 46:819–26.

5.Colberg SR., Sigal RJ., Yardley JE., Riddell MC., Dunstan DW., Dempsey PC, et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016. 39:2065–79.

6.Hur KY., Moon MK., Park JS., Kim SK., Lee SH., Yun JS., Committee of Clinical Practice Guidelines, Korean Diabetes Association, et al. 2021 Clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association. Diabetes Metab J. 2021. 45:461–81.

7.Matthews DR., Paldánius PM., Proot P., Chiang Y., Stumvoll M., Del Prato S; VERIFY Study Group. Glycaemic dura-bility of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019. 394:1519–29.

8.Choi JH., Lee KA., Moon JH., Chon S., Kim DJ., Kim HJ, et al. 2023 Clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association. Diabetes Metab J. 2023. 47:575–94.

9.Omboni S., Gazzola T., Carabelli G., Parati G. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies. J Hypertens. 2013. 31:455–67. discussion 467-8.

10.Kim HJ., Kim KI. Blood pressure target in type 2 diabetes mellitus. Diabetes Metab J. 2022. 46:667–74.

11.Yang YS., Kim HL., Kim SH., Moon MK. Lipid management in Korean people with type 2 diabetes mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis consensus statement. Diabetes Metab J. 2023. 47:1–9.

12.Heerspink HJL., Stefánsson BV., Correa-Rotter R., Chertow GM., Greene T., Hou FF., DAPA-CKD Trial Com-mittees and Investigators, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020. 383:1436–46.

13.Herrington WG., Staplin N., Wanner C., Green JB., Hauske SJ., Emberson JR., The EMPA-KIDNEY Collaborative Group, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023. 388:117–27.

14.Filippatos G., Anker SD., Agarwal R., Pitt B., Ruilope LM., Rossing P., FIDELIO-DKD Investigators, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation. 2021. 143:540–52.

15.Pitt B., Filippatos G., Agarwal R., Anker SD., Bakris GL., Rossing P., FIGARO-DKD Investigators, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021. 385:2252–63.

16.ElSayed NA., Aleppo G., Aroda VR., Bannuru RR., Brown FM., Bruemmer D., American Diabetes Association, et al. 14. Children and adolescents: standards of care in diabetes-2023. Diabetes Care. 2023. 46(Suppl 1):S230–53.

17.Shah AS., Zeitler PS., Wong J., Pena AS., Wicklow B., Arsla-nian S, et al. ISPAD clinical practice consensus guidelines 2022: type 2 diabetes in children and adolescents. Pediatr Diabetes. 2022. 23:872–902.

18.Kelly AS., Auerbach P., Barrientos-Perez M., Gies I., Hale PM., Marcus C., NN8022-4180 Trial Investigators, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020. 382:2117–28.

19.Inge TH., Jenkins TM., Xanthakos SA., Dixon JB., Daniels SR., Zeller MH, et al. Long-term outcomes of bariatric surgery in adolescents with severe obesity (FABS-5+): a prospective follow-up analysis. Lancet Diabetes Endocri-nol. 2017. 5:165–73.

20.Inge TH., Laffel LM., Jenkins TM., Marcus MD., Leibel NI., Brandt ML., Teen– Longitudinal Assessment of Bariatric Surgery (Teen-LABS) and Treatment Options of Type 2 Diabetes in Adolescents and Youth (TODAY) Consortia, et al. Comparison of surgical and medical therapy for type 2 diabetes in severely obese adolescents. JAMA Pediatr. 2018. 172:452–60.

21.Bjornstad P., Hughan K., Kelsey MM., Shah AS., Lynch J., Nehus E, et al. Effect of surgical versus medical therapy on diabetic kidney disease over 5 years in severely obese adolescents with type 2 diabetes. Diabetes Care. 2020. 43:187–95.